Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/jmcb/mjaa070 http://scihub22266oqcxt.onion/10.1093/jmcb/mjaa070 33377928!7799018!33377928     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Mol+Cell+Biol 2020 ; 12 (12): 980-986 Nephropedia Template TP {{tp|p=33377928|t=2020. The development of neutralizing antibodies against SARS-CoV-2 and their common features |pdf=|usr=}}{{33377928}} gab.com Text The development of neutralizing antibodies against SARS-CoV-2 and their common features JO: J Mol Cell Biol http://www.kidney.de/pget.php?&tw=1&pmid=33377928 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features. Twit Text FOAVip The development of neutralizing antibodies against SARS-CoV-2 and their common features ????J Mol Cell Biol http://www.kidney.de/pget.php?&tw=1&pmid=33377928 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33377928 #FOAvip English Wikipedia <ref>{{Cite pmid|33377928}}</ref> The development of neutralizing antibodies against SARS-CoV-2 and their common features #MMPMID33377928 Liu LD; Lian C; Yeap LS; Meng FL J Mol Cell Biol 2020[Nov]; 12 (12): 980-986 PMID33377928show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features. |Animals[MESH] |Antibodies, Monoclonal, Humanized/immunology/isolation & purification/therapeutic use[MESH] |Antibodies, Monoclonal, Murine-Derived/immunology/isolation & purification/therapeutic use[MESH] |Antibodies, Neutralizing/immunology/isolation & purification/*therapeutic use[MESH] |Antibodies, Viral/immunology/isolation & purification/*therapeutic use[MESH] |Antibody Diversity[MESH] |COVID-19/*immunology/*therapy/virology[MESH] |Drug Discovery[MESH] |Epitopes/chemistry/immunology[MESH] |Humans[MESH] |Mice[MESH] |Models, Molecular[MESH] |Pandemics[MESH] |SARS-CoV-2/*immunology[MESH]The development of neutralizing antibodies against SARS-CoV-2 and thei(epmc).pdf DeepDyve Pubget Overpricing